Efficacy of TCA Effect on Varicella Atrophic Scars
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00422539 |
Recruitment Status
: Unknown
Verified January 2007 by Shahid Beheshti University of Medical Sciences.
Recruitment status was: Recruiting
First Posted
: January 17, 2007
Last Update Posted
: January 17, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atrophic Varicella Scar | Drug: 70% trichloroacetic acid | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 100 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evaluation of Tri Chloro Acetic Acid (TCA) Effect on Atrophic Varicella Scars |
Study Start Date : | March 2006 |

- Objective Clearance(before and after photographies were taken)
- Subjective Clearance(according to the patients satisfaction)
- Adverse effects(assessed by clinician as erythema, pigmentary changes, scaring)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 45 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Atrophic varicella scar on face
Exclusion Criteria:
- Active varicella infection
- Active Herpetic infection
- Previous history of keloid formation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00422539
Contact: Behrooz Barikbin, M.D. | 98-21-22744393 ext 5 | bbarikbin@yahoo.com |
Iran, Islamic Republic of | |
Skin Research Center, Shohada-e Tajrish Hospital, shaheed Beheshti Medical University | Recruiting |
Tehran, Iran, Islamic Republic of, 198994148 |
Study Chair: | Parviz Toossi, M.D. | Skin Research Center of Shaheed Beheshti medical University | |
Principal Investigator: | Behrooz Barikbin, M.D. | Skin Research Center of Shaheed Beheshti Medical Universty |
ClinicalTrials.gov Identifier: | NCT00422539 History of Changes |
Other Study ID Numbers: |
SRC-BBA-1385-6-1 |
First Posted: | January 17, 2007 Key Record Dates |
Last Update Posted: | January 17, 2007 |
Last Verified: | January 2007 |
Keywords provided by Shahid Beheshti University of Medical Sciences:
trichloroacetic acid varicella scar |
Additional relevant MeSH terms:
Chickenpox Herpes Zoster Atrophy Herpesviridae Infections |
DNA Virus Infections Virus Diseases Pathological Conditions, Anatomical |